Nature Communications (Dec 2023)

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential

  • Jason Wallach,
  • Andrew B. Cao,
  • Maggie M. Calkins,
  • Andrew J. Heim,
  • Janelle K. Lanham,
  • Emma M. Bonniwell,
  • Joseph J. Hennessey,
  • Hailey A. Bock,
  • Emilie I. Anderson,
  • Alexander M. Sherwood,
  • Hamilton Morris,
  • Robbin de Klein,
  • Adam K. Klein,
  • Bruna Cuccurazzu,
  • James Gamrat,
  • Tilka Fannana,
  • Randy Zauhar,
  • Adam L. Halberstadt,
  • John D. McCorvy

DOI
https://doi.org/10.1038/s41467-023-44016-1
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT2A-Gq/11 and β-arrestin2 transducers, making their respective roles unclear. To elucidate this, we develop a series of 5-HT2A-selective ligands with varying Gq efficacies, including β-arrestin-biased ligands. We show that 5-HT2A-Gq but not 5-HT2A-β-arrestin2 recruitment efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT2A partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT2A Gq-efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT2A agonists. We also demonstrate that β-arrestin-biased 5-HT2A receptor agonists block psychedelic effects and induce receptor downregulation and tachyphylaxis. Overall, 5-HT2A receptor Gq-signaling can be fine-tuned to generate ligands distinct from classical psychedelics.